Last update 12 Dec 2024

EDP-1503

Overview

Basic Info

Drug Type
Live biotherapeutic products
Synonyms
EDP 1503
Target-
Mechanism
Bacteria replacements, Microbiome modulators
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Melanoma, Cutaneous MalignantMelanoma
Inactive Indication
Bladder CancerColorectal CancerEsophageal Carcinoma+ [8]
Originator Organization
The University of ChicagoThe University of Chicago
Active Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.The University of ChicagoThe University of Chicago
Inactive Organization
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with EDP-1503
NCT03775850 / CompletedPhase 1
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
NCT03595683 / Active, not recruitingPhase 2IIT
Phase II Dual-Cohort Study Evaluating the Effects of Pembrolizumab in the Presence of Gut Microbiota Modulation With EDP1503 in Advanced Melanoma Naïve or Refractory to Anti-PD1 Antibody
100 Clinical Results associated with EDP-1503
Login to view more data
100 Translational Medicine associated with EDP-1503
Login to view more data
100 Patents (Medical) associated with EDP-1503
Login to view more data
100 Deals associated with EDP-1503
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 2
US
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Bladder CancerPhase 2
CA
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Colorectal CancerPhase 2
US
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Colorectal CancerPhase 2
CA
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Esophageal CarcinomaPhase 2
US
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Esophageal CarcinomaPhase 2
CA
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Microsatellite Instability cancerPhase 2
US
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Microsatellite Instability cancerPhase 2
CA
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Non-Small Cell Lung CancerPhase 2
US
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Non-Small Cell Lung CancerPhase 2
CA
Evelo Biosciences, Inc.Evelo Biosciences, Inc.
19 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03775850 (EDP1503-101, AACR2021)
ManualManual
Phase 1/2
Triple Negative Breast Cancer
15
tofmeaiakt(dpsiumgtru) = sfktwyafzi tzbwaqdjid (odtgcomytd )
View more
Positive
15 Feb 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free